

Saturday 9 <sup>th</sup> October 2021			
All times: CEST (Central European Summer Time, GMT+2)			
Time	Session		
13.00-13:05	<b>Welcome Address</b> Silke Gillessen and Aurelius Omlin on behalf of APCCC		
13.05 – 15.00 <b>Session 1</b>	<b>Management of newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC)</b>	<b>Chairs: Bertrand Tombal and Nick James</b>	<b>Duration</b>
	What is the evidence for “triplet therapy” (ADT + radiation of the primary + additional systemic therapy)?	Karim Fizazi	12 min
	What is the evidence for “triplet therapy” (ADT + docetaxel + additional systemic therapy)?	Ian Davis	12 min
	Do different subgroup of patients need different treatments?	Chris Sweeney	12 min
	What can meta-analyses, network meta-analyses and subgroup analyses tell us about treatment options: Pearls and pitfalls	Claire Vale	12 min
	Are there still patients where treatment with ADT alone is appropriate?	Rob Jones	10 min
	Can molecular markers inform treatment decision in mHSPC?	Himisha Beltran	10 min
14.15 – 14.30	Discussion		
14.30 – 14.50	<b>Consensus questions</b>		
14:50 - 15.00	Break		
15.00 – 17.00 <b>Session 2</b>	<b>PSMA in diagnostics and therapy</b>	<b>Chairs: Alberto Bossi, Neal Shore</b>	<b>Duration</b>
	PSMA – background	Derya Tilki	10 min
	PSMA PET: Really the best modality for staging to improve clinical outcomes?	Piet Ost	12 min
	PSMA –based imaging: Navigating the pitfalls of the different tracers	Stefano Fanti	12 min
	Do we need the second PET (FDG) for patient selection? (including SUV for selection of PSMA therapy)	Michael Hofman	10 min
	Best use of Lutetium-PSMA and where to put it in sequencing therapies including treatment monitoring	Charles Ryan	12 min
	Novel PSMA targeted agents (BITE’s, cellular therapies, actinium, thorium...)	Eleni Efstathiou	10 min
16.15 – 16.30	Discussion		
16.30 – 16.50	<b>Consensus questions</b>		
16.50 – 17.00	Break		
17.00 – 19.00 <b>Session 3</b>	<b>PARP inhibitors and beyond: Molecular characterisation of tissue and blood</b>	<b>Chairs: Nicolas Mottet, Matthew Smith</b>	<b>Duration</b>
	Who needs germline testing and what should be tested?	Dana Rathkopf	12 min
	Somatic testing – When and what? (including mismatch repair evaluation)	Maha Hussain	12 min
	Tumor molecular testing – tissue vs liquid biopsy	Andrew Armstrong	12 min

	<b>DNA repair defect aberrations – What are the differences between them and what is the impact on patient management?</b>	Johann De Bono	15 min
	<b>Novel and not so novel agents and where to place them in the treatment sequence?</b>	Eric Small	15 min
<b>18.15 – 18.30</b>	<b>Discussion</b>		
<b>18.30 – 18.50</b>	<b>Consensus questions</b>		
<b>18.50 – 19.00</b>	<b>Break</b>		
<b>19.00 – 19.30</b>	<b>“Aperitivo”- Challenge the Experts (3 parallel Breakout Sessions) with limited number of participants</b>		
<b>Fully Booked</b>	<b>Topic 1: Management of newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC)</b>	Nick James, Chris Sweeney	30 min
<b>Fully Booked</b>	<b>Topic 2: PSMA in diagnostics and therapy</b>	Stefano Fanti, Michael Morris	30 min
<b>Fully Booked</b>	<b>Topic 3: PARP inhibitors and beyond: Molecular characterisation of tissue and blood</b>	Johann de Bono, Karim Fizazi	30 min